Medical/Pharmaceuticals
Asieris Pharmaceuticals Releases 2024 Annual Report, with Revenue Exceeding RMB 200M in 1st Year of Commercialization and Innovative Portfolio Accelerating Toward Launch
SHANGHAI, April 18, 2025 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2024 Annual Report, highlighting a bold and determined journey forward. With a specialty pharma strategy and operational efficiency, the company exceeded its commercialization targets and advanced its innovative p...
Akeso's Ebdarokimab ( IL - 12/IL - 23 Dual - Targeted Monoclonal Antibody) Approved in China for Moderate - to - Severe Plaque Psoriasis
HONG KONG, April 18, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the National Medical Products Administration (NMPA) for the tre...
WuXi Biologics Completes First Commercial PPQ Campaign at 15,000L Production Line in Hangzhou Site
- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,000L single-use bioreactors - Proprietary process innovation reduces protein cost by nearly 70% while boosting yield 20% - As the company's largest operational single-use bioreactor...
Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano
Highlights * Clarity has signed a commercial-scale agreement with Nusano, Inc. ("Nusano") for supply of copper-64 (Cu-64 or64Cu) isotope. * The 190,000 square foot Nusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci (37,000 GBq) of copper-64 per day at capaci...
Caliway Selected to Present CBL-514 Phase 2 Study Results for Dercum's Disease at World Orphan Drug Congress USA 2025
* CBL-514, Caliway's novel small molecule drug, was selected for data presentation at the World Orphan Drug CongressUSA 2025, highlighting its promising Phase 2 study results (CBL-0201DD) for Dercum's Disease Treatment. * The Phase 2 topline results met all primary and secondary endpoints, wit...
Earendil Labs Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Bispecific Antibodies for Autoimmune and Inflammatory Bowel Diseases
MIDDLETOWN, Del., April 17, 2025 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the...
Fangzhou Launches Partnership for "AI + Hepatitis Prevention & Control Training Center" at the Greater Bay Area International Liver Disease Forum
GUANGZHOU, China, April 16, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven healthcare solutions, partnered with the Guangdong Provincial Liver Disease Institute at the 2025 Greater Bay Area International Liver Disease Forum to launch the "AI + ...
Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer
Daly, a 30-year veteran of the healthcare industry, is the latest leadership
addition to help Terumo BCT unite business areas and fuel enterprise growth
LAKEWOOD, Colo., April 16, 2025 /PRNewswire/ -- Terumo Blood and Cell
Technologies
Terumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US
– Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort – SOMERSET, N.J., April 16, 2025 /PRNewswire/ -- Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced that Medis QFR 3.0, an FDA-cle...
Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report
SHANGHAI, April 16, 2025 /PRNewswire/ -- On April 15, 2025, Henlius (2696.HK) released the "2024 Environmental, Social, and Governance (ESG) Report" (hereinafter referred to as the "ESG Report" or "Report"). This marks the sixth consecutive year that the company has submitted an ESG-related repor...
Global Health Innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact
* Winners of the ADGHW Innovation Awards 2025 addressed prenatal gene editing, robotic organ transplantation, precision drug delivery, and novel pain treatments * Recipients include the Children's Hospital of Philadelphia, University of Pennsylvania, King Faisal Specialist Hospital & Research...
XellSmart's Allogeneic iPSC-derived Cell Therapies for Parkinson's Disease and ALS Officially Approved by the U.S. FDA for Phase I Clinical Trials
SUZHOU, China, April 15, 2025 /PRNewswire/ -- In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submitted by XellSmart Biopharmaceutical (Suzhou) Co., Ltd. for its universal allogeneic off-the-shelf iPS-deri...
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
HIGHLIGHTS * The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of67Cu-SAR-bisPSMA.This follows the recent recommendation by the Safety Review Committee (SRC) after the successful completion of t...
Pilatus Biosciences to Present Research on PLT012 at AACR 2025
Novel Immunometabolism Approach Targets Immune-Cold Solid Tumors DOVER, Del. and EPALINGES, Switzerland, April 15, 2025 /PRNewswire/ -- Pilatus Biosciences, pioneering biologics targeting metabolic checkpoints, will present new research on its lead candidate, PLT012, at the American Association ...
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
KYOTO, Japan, April 15, 2025 /PRNewswire/ -- Rege Nephro Co., Ltd. (Headquarter: Kyoto, Japan; Chief Executive Officer: Akifumi Morinaka) has announced that it has successfully acquired Tamibarotene-related clinical and non-clinical assets from Syros Pharmaceuticals, Inc. (Headquarters:Boston, MA;...
PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug Discovery for Protein-Protein Interaction Targets
Strategic Partnership Aims to Create Novel Drug Discovery Pipeline for Unmet Medical Needs by Combining PPI Control Technology with AI Drug Discovery Platform TOKYO, April 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company ...
MGI Tech Celebrates 10 Years of DNBSEQ™ Technology: Driving Genomics Forward with Speed, Scale, and Accessibility
SHENZHEN, China, April 13, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a
company committed to building core tools and technologies that drive innovation
in life science, proudly marks a decade since the commercialization of its
proprietaryDNBSEQ™ sequencing technology
Global First Engineered Exosome with INCI Name -- ImmVira Leads a New Era in International Cosmetic Ingredients
SUZHOU, China, April 10, 2025 /PRNewswire/ -- EonveLab, a subsidiary of ImmVira Group ("ImmVira," or the "Company"), recently announced that its in-house developed engineered exosome product, MVR-EX103, developed for treating superficial skin depressions, has successfully passed the review of th...
Florida Theranostics Brings Cutting-Edge United Imaging Digital PET/CT to Palm Beach County, Florida
The uMI Panorama™ from United Imaging is the first in Florida. HOUSTON, April 10, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, will feature its uMI Panorama at a state-of-the-art new facility inJupiter, FL. Focused on patient-centered and preci...
Longevity and precision medicine driving the agenda at Abu Dhabi Global Health Week
* Global initiative addressing personalised and preventative health to be launched during the event ABU DHABI, UAE, April 10, 2025 /PRNewswire/ -- With rising global demand for more personalised and effective healthcare solutions, the Department of Health -Abu Dhabi (DoH) , the regulator of the...
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 319 media titles]
2026-09-03 23:53Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36